Patents
2026.01.26
TAHO Pharmaceuticals Receives Taiwan Patent Allowance for TAH2231, A Naloxone Buccal Film for Opioid Overdose Rescue
TAHO Pharmaceuticals Receives Taiwan Patent Allowance for TAH2231, A
Naloxone Buccal Film for Opioid Overdose Rescue
Taipei — January 23, 2026 – TAHO Pharmaceuticals Ltd. (Stock ticker: 6467)announced that its proprietary product, TAH2231, has received a Notice ofAllowance from the Taiwan Intellectual Property Office for the patent titled "Naloxone Buccal Film Product and Uses Thereof".
TAH2231 is a novel formulation being developed by TAHO to help address the escalating global opioid overdose crisis. Unlike traditional injections that may require greater preparation and training, or certain nasal sprays that is relatively bulky and inconvenient to carry, TAH2231 is designed as a small, thin innovative buccal film for discreet portability and ease of use. This technology incorporates Naloxone, the standard rescue medication for opioid overdose, into a tiny and thin film that dissolves rapidly and deliver the active ingredient via the oral mucosa, blocking the life-threatening effects of opioids immediately.
This patent allowance reinforces TAHO’s expertise in drug delivery innovation and expands the Company’s intellectual property portfolio in Taiwan and internationally. The additional IP protection is expected to support future commercialization and strengthen the product’s appeal for potential licensing.
About TAH2231
Opioid misuse and overdose-related deaths have become a major global public health challenge, particularly in the United States, highlighting the urgent need for rapid and accessible rescue interventions. However, many current rescue options can be bulky or highly conspicuous, which may discourage consistent carry among high-risk individuals.
TAH2231 was developed to address the current trade-off between discretion and accessibility associated with existing products. Its ultra-thin, compact profile is intended to fit easily into a wallet or pocket, supporting routine carry and immediate availability when needed. In addition, the film is designed for non- invasive administration by placing it against the inner cheek, which may help reduce bystander hesitation during emergencies, while enabling simple and rapid delivery of naloxone. By overcoming these longstanding limitations, TAH2231 meets a clear market's need for a truly user-friendly, life-saving rescue formulation.
Naloxone Buccal Film for Opioid Overdose Rescue
Taipei — January 23, 2026 – TAHO Pharmaceuticals Ltd. (Stock ticker: 6467)announced that its proprietary product, TAH2231, has received a Notice ofAllowance from the Taiwan Intellectual Property Office for the patent titled "Naloxone Buccal Film Product and Uses Thereof".
TAH2231 is a novel formulation being developed by TAHO to help address the escalating global opioid overdose crisis. Unlike traditional injections that may require greater preparation and training, or certain nasal sprays that is relatively bulky and inconvenient to carry, TAH2231 is designed as a small, thin innovative buccal film for discreet portability and ease of use. This technology incorporates Naloxone, the standard rescue medication for opioid overdose, into a tiny and thin film that dissolves rapidly and deliver the active ingredient via the oral mucosa, blocking the life-threatening effects of opioids immediately.
This patent allowance reinforces TAHO’s expertise in drug delivery innovation and expands the Company’s intellectual property portfolio in Taiwan and internationally. The additional IP protection is expected to support future commercialization and strengthen the product’s appeal for potential licensing.
About TAH2231
Opioid misuse and overdose-related deaths have become a major global public health challenge, particularly in the United States, highlighting the urgent need for rapid and accessible rescue interventions. However, many current rescue options can be bulky or highly conspicuous, which may discourage consistent carry among high-risk individuals.
TAH2231 was developed to address the current trade-off between discretion and accessibility associated with existing products. Its ultra-thin, compact profile is intended to fit easily into a wallet or pocket, supporting routine carry and immediate availability when needed. In addition, the film is designed for non- invasive administration by placing it against the inner cheek, which may help reduce bystander hesitation during emergencies, while enabling simple and rapid delivery of naloxone. By overcoming these longstanding limitations, TAH2231 meets a clear market's need for a truly user-friendly, life-saving rescue formulation.